<unk> , sold under the brand name Dovato, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains<unk> , an integrase inhibitor, and lamivudine, a reverse-transcriptase inhibitor. It is taken by mouth. It was approved for use in the United States in April 2019, and in the European Union in July 2019. The most common side effects are headache, diarrhoea, nausea, and difficulty sleeping. The most common serious side effects are allergic reactions, including rash and severe liver problems.
Dolutegravir/lamivudine
Abacavir/lamivudine
Lamivudine/tenofovir
Lamivudine/raltegravir
Lamivudine/zidovudine
Atazanavir/ritonavir
Dolutegravir/rilpivirine
Doravirine/lamivudine/tenofovir